CoChat

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Objective: To evaluate the effects of the glucagon-like peptide-1 receptor agonist lixisenatide on elevated liver blood tests in patients with type 2 diabetes. Design: Systematic review. Data sources: Electronic and manual searches were combined. Study selection: Randomised controlled trials (RCTs) on lixisenatide versus placebo or active comparators for type 2 diabetes were included. Participants: Individual patient data were retrieved to calculate outcomes for patients with elevated liver blood tests. Main outcome measures: Normalisation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Data synthesis: The results of included trials were combined in meta-analyses. Sequential, subgroup and regression analyses were performed to evaluate heterogeneity and bias. Results: We included 12 RCTs on lixisenatide versus placebo and 3 RCTs with the active comparators liraglutide, exenatide or sitagliptin. The mean treatment duration was 29 weeks. Lixisenatide increased the proportion of patients with normalisation of ALT (risk difference: 0.07; 95% CI 0.01 to 0.14; number needed to treat: 14 patients, p=0.042). The effect was not confirmed in sequential analysis. No effects of lixisenatide were identified on AST, alkaline phosphatase or bilirubin. No evidence of bias was identified. Mixed effect multilevel meta-regression analyses suggest that the benefit of lixisenatide on ALT was limited to patients who were overweight or obese. Conclusions: This review suggests that lixisenatide increases the proportion of obese or overweight patients with type 2 diabetes who achieve normalisation of ALT. Additional research is needed to determine if the findings translate to clinical outcome measures. Trial registration number: PROSPERO; CRD42013005779.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2014-005325

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial flow chart.
Figure 1 Trial flow chart.CC BY-NC · PubMed Central
Figure 2 Random effects meta-analysis of randomised controlled trials on normalisation of alanine aminotransferase (ALT). The result of the analysis is expressed as the risk difference (RD) with 95% CIs and level of significance (p value). The intervention comparisons are lixisenatide versus placebo or active interventions. The included patients have type 2 diabetes and elevated ALT at baseline. The outcome measure is normalisation of ALT.
Figure 2 Random effects meta-analysis of randomised controlled trials on normalisation of alanine aminotransferase (ALT). The result of the analysis is expressed as the risk difference (RD) with 95% CIs and level of significance (p value). The intervention comparisons are lixisenatide versus placebo or active interventions. The included patients have type 2 diabetes and elevated ALT at baseline. The outcome measure is normalisation of ALT.CC BY-NC · PubMed Central
Figure 3 Sequential analysis of risk ratios (random effects) in randomised controlled trials on lixisenatide versus placebo or active interventions for patients with type 2 diabetes and elevated alanine aminotransferase (ALT) at baseline. The analysis was performed with α 5%, power 80%, model-based diversity correction 12%, relative risk reduction 8% and control group incidence rate 51%. The outcome measure is normalisation of ALT. The analysis shows that lixisenatide has a beneficial effect on normalisation of ALT when assessed using the traditional 5% level of significance (the horizontal line), but not after adjusting for cumulative assessment (the trial monitoring boundary).
Figure 3 Sequential analysis of risk ratios (random effects) in randomised controlled trials on lixisenatide versus placebo or active interventions for patients with type 2 diabetes and elevated alanine aminotransferase (ALT) at baseline. The analysis was performed with α 5%, power 80%, model-based diversity correction 12%, relative risk reduction 8% and control group incidence rate 51%. The outcome measure is normalisation of ALT. The analysis shows that lixisenatide has a beneficial effect on normalisation of ALT when assessed using the traditional 5% level of significance (the horizontal line), but not after adjusting for cumulative assessment (the trial monitoring boundary).CC BY-NC · PubMed Central
Figure 4 Mixed model meta-regression analysis of the effect of lixisenatide versus placebo on normalisation of alanine aminotransferase (ALT). Included patients have type 2 diabetes and elevated ALT at baseline. The outcome measure is normalisation of ALT. The figure shows the estimated intervention effect (normalisation of ALT) on the log-OR scale in relation to the baseline body weight of included patients from 12 randomised placebo-controlled trials. The size (area) of each circle is inversely proportional to the variance of the log OR (the larger the circle the lesser the variance).
Figure 4 Mixed model meta-regression analysis of the effect of lixisenatide versus placebo on normalisation of alanine aminotransferase (ALT). Included patients have type 2 diabetes and elevated ALT at baseline. The outcome measure is normalisation of ALT. The figure shows the estimated intervention effect (normalisation of ALT) on the log-OR scale in relation to the baseline body weight of included patients from 12 randomised placebo-controlled trials. The size (area) of each circle is inversely proportional to the variance of the log OR (the larger the circle the lesser the variance).CC BY-NC · PubMed Central
Figure 5 Random effects meta-analysis of randomised controlled trials on normalisation of aspartate aminotransferase (AST). The result of the analysis is expressed as the risk difference (RD) with 95% CIs and level of significance (p value). The intervention comparisons are lixisenatide versus placebo or active interventions. The included patients have type 2 diabetes and elevated ALT at baseline. The outcome measure is normalisation of ALT.
Figure 5 Random effects meta-analysis of randomised controlled trials on normalisation of aspartate aminotransferase (AST). The result of the analysis is expressed as the risk difference (RD) with 95% CIs and level of significance (p value). The intervention comparisons are lixisenatide versus placebo or active interventions. The included patients have type 2 diabetes and elevated ALT at baseline. The outcome measure is normalisation of ALT.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 40 references

Research works printed but not linked: 1

  1. Ratner RE, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S). Diabetologia 2011;54:785.

Cited by

See all 62

Metadata

Authors
Gluud, L. L., Knop, F. K., & Vilsbøll, T.
Affiliations
University of Copenhagen (DK)
Corresponding author
Gluud, Lise L
Venue
BMJ Open
Publisher
BMJ
Published
2014-12
Volume
4
Issue
12
Pages
e005325
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2138748324
Cited by
59
References
40
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 10 · 2019: 7 · 2018: 6 · 2017: 2 · 2016: 6 · 2015: 3
FWCI
0.58
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Sanofi
  • Novo Nordisk Fonden (NNF12OC1015904)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
lixisenatide, type 2 diabetes, liver transaminases, alanine aminotransferase, aspartate aminotransferase, GLP-1 receptor agonists, obesity, overweight, liver function tests, liraglutide, exenatide, sitagliptin
MeSH terms
Glucagon-Like Peptide-2 Receptor, Alanine Transaminase, Aspartate Aminotransferases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Peptides, Regression Analysis, Biomarkers, Randomized Controlled Trials as Topic, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. https://app.cochat.ai/papers/10.1136/bmjopen-2014-005325
The paper
Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014). Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open. https://doi.org/10.1136/bmjopen-2014-005325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.